Melanie A Paquette

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. pmc Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias
    Melanie A Paquette
    Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, Oregon, USA
    Neuroreport 19:111-5. 2008
  2. pmc The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism
    Melanie A Paquette
    Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR 97239, USA
    Psychopharmacology (Berl) 204:743-54. 2009
  3. ncbi request reprint Amphetamine-evoked rotation requires newly synthesized dopamine at 14 days but not 1 day after intranigral 6-OHDA and is consistently dissociated from sensorimotor behavior
    Melanie A Paquette
    Department of Psychology, Arizona State University, Tempe, AZ 85287 1104, USA
    Behav Brain Res 200:197-207. 2009
  4. pmc MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism
    Melanie A Paquette
    Department of Veterans Affairs Medical Center, Portland, OR 97239, USA
    Neuropharmacology 58:1002-8. 2010
  5. ncbi request reprint Assessment of recovery in the hemiparkinson rat: drug-induced rotation is inadequate
    Eddie Castañeda
    Molecular and Structural Neurobiology and Gene Therapy Program, Department of Psychology, Arizona State University, Tempe, Arizona 85287 1104, United States
    Physiol Behav 84:525-35. 2005
  6. pmc Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors
    Melanie A Paquette
    Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX, USA
    Eur J Neurosci 36:3224-34. 2012
  7. pmc The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat
    Nirmal Bhide
    Behavioral Neuroscience Program, Department of Psychology, Binghamton University, Binghamton, NY 13902 6000, USA
    Psychopharmacology (Berl) 227:533-44. 2013

Collaborators

Detail Information

Publications7

  1. pmc Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias
    Melanie A Paquette
    Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, Oregon, USA
    Neuroreport 19:111-5. 2008
    ..Antidyskinetic effects of dextromethorphan may be mediated via mechanisms other than NMDA, including the sigma-1 receptor and other binding sites common to dextromethorphan and BMY-14802...
  2. pmc The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism
    Melanie A Paquette
    Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR 97239, USA
    Psychopharmacology (Berl) 204:743-54. 2009
    ..In the 6-hydroxydopamine (6-OHDA) rat model of PD, L-DOPA induces a similar phenomenon, which has been termed abnormal involuntary movement (AIM). We previously demonstrated that BMY-14802 suppresses AIM expression in this model...
  3. ncbi request reprint Amphetamine-evoked rotation requires newly synthesized dopamine at 14 days but not 1 day after intranigral 6-OHDA and is consistently dissociated from sensorimotor behavior
    Melanie A Paquette
    Department of Psychology, Arizona State University, Tempe, AZ 85287 1104, USA
    Behav Brain Res 200:197-207. 2009
    ..The present data do not support the hypothesis that enhanced DA synthesis is required to express paradoxical rotation. Therefore, alternative mechanisms that may enhance cytoplasmic DA to produce paradoxical rotation are discussed...
  4. pmc MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism
    Melanie A Paquette
    Department of Veterans Affairs Medical Center, Portland, OR 97239, USA
    Neuropharmacology 58:1002-8. 2010
    ..We conclude that noncompetitive NMDA antagonists are unlikely to suppress dyskinesia clinically without worsening parkinsonism...
  5. ncbi request reprint Assessment of recovery in the hemiparkinson rat: drug-induced rotation is inadequate
    Eddie Castañeda
    Molecular and Structural Neurobiology and Gene Therapy Program, Department of Psychology, Arizona State University, Tempe, Arizona 85287 1104, United States
    Physiol Behav 84:525-35. 2005
    ....
  6. pmc Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors
    Melanie A Paquette
    Department of Pharmacology, University of Texas Health Science Center, San Antonio, TX, USA
    Eur J Neurosci 36:3224-34. 2012
    ..Combined with previous work from our group, our results support the investigation of 5-HT(1A) agonists as pharmacotherapies for LID in PD patients...
  7. pmc The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat
    Nirmal Bhide
    Behavioral Neuroscience Program, Department of Psychology, Binghamton University, Binghamton, NY 13902 6000, USA
    Psychopharmacology (Berl) 227:533-44. 2013
    ..The purported sigma-1 antagonist, BMY-14802 has been previously demonstrated to reduce L-DOPA induced dyskinesia in a 5-HT1A receptor dependent manner...